The Lancet infectious diseases
The most recent articles from:
Lancet Infect Dis
-
Randomized Controlled Trial
Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial.
Dengue infection is the most common mosquito-borne viral disease worldwide, but no suitable antiviral drugs are available. We tested the α-glucosidase inhibitor celgosivir as a treatment for acute dengue fever. ⋯ STOP Dengue Translational Clinical Research.